Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,598.00
Bid: 1,597.50
Ask: 1,598.00
Change: -6.50 (-0.41%)
Spread: 0.50 (0.031%)
Open: 1,613.00
High: 1,613.00
Low: 1,589.00
Prev. Close: 1,604.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Unilever CEO set to leave after GSK debacle, arrival of activist investor

Mon, 26th Sep 2022 11:00

CEO Jope to retire at end 2023

*

Board begins search for successor

*

Peltz 'looking forward' to being part of choosing a new CEO

*

Shares hit highest in more than a year on news

Sept 26 (Reuters) - Unilever said CEO Alan Jope would retire at the end of 2023, announcing the move less than a year after a bungled attempt to buy GSK's consumer healthcare business, and two months after activist investor Nelson Peltz joined the board.

The British consumer products maker said its board would start a formal search for a successor to Jope, a Unilever veteran who took up his role at the start of 2019, considering both internal and external candidates.

Unilever's shares rose almost 4% in early trading, hitting their highest since August last year. They were up 1.2% at 1150 GMT.

The company's search begins at a time of soaring food and energy prices which are hitting household budgets and hurting consumer confidence. The company will be looking for a new CEO at the same time as rival Reckitt, the maker of Dettol products and Finish dish soap.

Unilever has had a rocky start to the year after mounting three bids for the consumer health arm of GlaxoSmithKline , - one for as much as 50 billion pounds ($53.14 billion).

The move was met with disapproval from shareholders, some of whom also criticised Unilever for prioritising sustainability over core growth.

"This may signal more welcome future change at Unilever," Tineke Frikee, fund manager at Unilever investor Waverton Asset Management, said.

"The unappealing plan to buy consumer healthcare from GlaxoSmithKline has tainted Mr Jope’s track record somewhat so a fresh start from a new CEO could convince investors Unilever’s momentum is trending upwards again."

The company in January also announced plans to cut about 1,500 management jobs and reshape its business to focus on five main product areas, days after it was revealed that Peltz, via his Trian Partners vehicle, had built a stake in Unilever.

Trian told Reuters in a statement that it was sorry to learn of Jope's decision to retire.

"As a board member, Trian’s CEO Nelson Peltz looks forward to continuing to work closely with Alan until his departure and to being part of the process of choosing a new leader for the company," it added.

A Unilever spokesperson said the company is "fully committed to the organisational changes" and that Jope is "completely committed to delivering against that strategy."

'A MIXED BAG'

Jope has worked at Unilever for more than 35 years, holding various senior leadership positions, including being head of the personal care division from 2014.

"I think Jope’s tenure as CEO was a bit of a mixed bag," Jack Martin, fund manager at Unilever shareholder Oberon Investments, said. "It has been a very impressive career nonetheless, joining as a trainee in the 80’s and ending up as CEO of one of the UK’s largest listed companies,"

Unilever's shares have underperformed European consumer staples and discretionary indices, as well as most rivals since Jope became CEO.

"Our immediate concern is that this leaves 15 months until his retirement with a CEO who might be seen to have lost credibility with employees and other stakeholders," RBC analyst James Edwardes Jones said.

"This at a time when Unilever will be implementing and bedding down a fundamental reorganisation, not to mention dealing with a challenging macro-economic environment."

A source familiar with the matter said Unilever's "unusual" decision to tell the market more than a year before Jope leaves stems from concerns that the news would have leaked before being officially announced.

"While his has undoubtedly been a great career, investors are likely to see this as a positive change, as the company has struggled in recent years to convince investors that it has the right brands and strategy to be a mid-single digit growth company," Bernstein analyst Bruno Monteyne said.

More News
17 Aug 2023 11:56

LONDON MARKET MIDDAY: Stocks down over US rate hike worries

(Alliance News) - Stock prices in Europe were lower at midday on Thursday, after the US Federal Reserve warned that a further interest rate hike may be on the cards.

Read more
17 Aug 2023 08:53

LONDON MARKET OPEN: Stocks fall further after hawkish US Fed minutes

(Alliance News) - Stock prices in London opened in the red on Thursday, amid renewed concerns about further US interest rate increases.

Read more
13 Aug 2023 14:06

Sunday newspaper round-up: White Hydrogen, Bank of England, AI

(Sharecast News) - America's Geological survey estimates that if even a small fraction of naturally occurring - and clean or so-called 'white' - hydrogen beneath the earth's surface were recovered, that would last for hundreds of years. Among the backers of the hydrogen industry is Bill Gates, who ploughed $90m into Koloma, a company hunting for natural hydrogen along the US's Midcontinental Rift System. White hydrogen has also been discovered in Europe, in France's Lorraine region. Nonetheless, the true potential of the stuff will hinge on the findings from those early projects, says Philip Ball, research fellow at Keele University. - Guardian

Read more
10 Aug 2023 15:46

UK dividends calendar - next 7 days

Friday 11 August 
Blackrock Latin American Investment Trust PLCdividend payment date
Caffyns PLCdividend payment date
CMC Markets PLCdividend payment date
Montanaro UK Smaller Cos Investment Trust PLCdividend payment date
Next 15 Group PLCdividend payment date
Ninety One PLC and Ltddividend payment date
Schroder European Real Estate Investment Trust PLCdividend payment date
Sportech PLCspecial dividend payment date
Telecom Plus PLCdividend payment date
Triad Group PLCdividend payment date
Wincanton PLCdividend payment date
Monday 14 August 
Mountview Estates PLCdividend payment date
Tuesday 15 August 
Tatton Asset Management PLCdividend payment date
Wednesday 16 August 
Murray International Trust PLCdividend payment date
Shoe Zone PLCdividend payment date
Thursday 17 August 
4imprint Group PLCex-dividend payment date
abrdn PLCex-dividend payment date
abrdn Property Income Trust Ltdex-dividend payment date
Anglo American PLCex-dividend payment date
Baillie Gifford UK Growth Trust PLCex-dividend payment date
Berkeley Group Holdings PLCex-dividend payment date
BlackRock Sustainable American Income Trust PLCex-dividend payment date
Bridgepoint Group PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
ConvaTec Group PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
GSK PLCex-dividend payment date
Henderson Opportunities Trust PLCex-dividend payment date
Hiscox Ltdex-dividend payment date
Impact Healthcare REIT PLCex-dividend payment date
Imperial Brands PLCex-dividend payment date
Investec PLC and Ltdex-dividend payment date
iomart Group PLCex-dividend payment date
Keller Group PLCex-dividend payment date
Lancashire Holdings Ltdex-dividend payment date
London Stock Exchange Group PLCex-dividend payment date
Montanaro European Smaller Cos Trust PLCex-dividend payment date
Murray Income Trust PLCex-dividend payment date
NextEnergy Solar Fund Ltdex-dividend payment date
Octopus Renewables Infrastructure Trust PLCex-dividend payment date
Pershing Square Holdings Ltdex-dividend payment date
Rotork PLCex-dividend payment date
Sabre Insurance Group PLCex-dividend payment date
Schroders PLCex-dividend payment date
Sirius Real Estate Ltddividend payment date
Tritax EuroBox PLCex-dividend payment date
UK Commercial Property REIT Ltdex-dividend payment date
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
7 Aug 2023 08:12

PRESS: Inflexion among firms looking to buy Haleon's nicotine business

(Alliance News) - Sky News reported on Sunday that Inflexion Private Equity Partners is among suitors for Haleon PLC's Nicotinell anti-smoking aid.

Read more
3 Aug 2023 16:31

GSK Nigeria calls an end to its business, to return cash

ABUJA, Aug 3 (Reuters) - GlaxoSmithKline (GSK) Nigeria said on Thursday it plans to stop doing business after evaluating the options for moving to a third-party distribution model for its drugs and consumer healthcare goods.

Read more
2 Aug 2023 20:45

TOP NEWS: GSK sues Pfizer over patent infingements for RSV vaccine

(Alliance News) - GSK PLC on Wednesday sued Pfizer Inc over patent infringement, alleging Pfizer's respiratory syncytial virus vaccine steals key elements of GSK's version.

Read more
2 Aug 2023 15:14

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in a U.S. court on Wednesday, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 14:28

GSK sues Pfizer in US for patent infringement over RSV vaccine

Aug 2 (Reuters) - British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its rival RSV shot Arexvy.

Read more
2 Aug 2023 10:41

Sensodyne maker Haleon's shiny forecast signals price hikes unlikely to dent demand

Shares down 1% on slight decline in H1 adj operating margin

*

Read more
2 Aug 2023 08:23

TOP NEWS: Haleon boosts annual guidance after solid first half

(Alliance News) - Haleon PLC on Wednesday upped its annual organic revenue growth guidance following a solid revenue performance in the first half of 2023.

Read more
31 Jul 2023 19:42

IN BRIEF: GSK hails US FDA approval for cancer treatment, Jemperli

GSK PLC - London-based pharmaceutical company - Jemperli plus chemotherapy approved in the US by the Food & Drug Administration as the first new frontline treatment option in decades for primary advanced or recurrent endometrial cancer. Notes Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy. Hesham Abdullah, senior vice president and global head of oncology development at GSK, says: "Today's approval underscore our belief in the potential for Jemperli to transform cancer treatment as a backbone immuno-oncology therapy."

Read more
31 Jul 2023 12:21

DIRECTOR DEALINGS: Qinetiq, Tesco and GSK executives sell shares

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced late last week and not separately reported by Alliance News:

Read more
31 Jul 2023 09:16

LONDON BROKER RATINGS: Oddo BHF raises IAG to 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
26 Jul 2023 11:06

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

Q2 sales and earnings beat estimates

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.